Truist Financial Corp Purchases 98,903 Shares of Johnson & Johnson (NYSE:JNJ)

Truist Financial Corp grew its position in Johnson & Johnson (NYSE:JNJ) by 4.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,122,856 shares of the company’s stock after acquiring an additional 98,903 shares during the period. Truist Financial Corp owned about 0.09% of Johnson & Johnson worth $310,277,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Eagle Asset Management Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $1,446,000. CIBC Private Wealth Group LLC grew its holdings in Johnson & Johnson by 0.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 717,254 shares of the company’s stock valued at $112,422,000 after buying an additional 3,938 shares in the last quarter. Royal London Asset Management Ltd. increased its position in Johnson & Johnson by 3.4% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,619,599 shares of the company’s stock worth $253,856,000 after buying an additional 53,116 shares during the period. ROI Financial Advisors LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $447,000. Finally, Edge Capital Group LLC grew its stake in shares of Johnson & Johnson by 12.0% in the fourth quarter. Edge Capital Group LLC now owns 111,673 shares of the company’s stock valued at $17,504,000 after acquiring an additional 12,000 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 0.4 %

JNJ opened at $162.02 on Tuesday. The company has a market cap of $389.93 billion, a P/E ratio of 10.10, a PEG ratio of 2.69 and a beta of 0.53. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $162.30 and its 200-day moving average is $154.18. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the business posted $2.80 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. TD Securities dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Morgan Stanley raised their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Friday, September 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Monday. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.